Unknown

Dataset Information

0

Comparison of isoflurane and propofol sedation in critically ill COVID-19 patients-a retrospective chart review.


ABSTRACT:

Purpose

In this retrospective study, we compared inhaled sedation with isoflurane to intravenous propofol in invasively ventilated COVID-19 patients with ARDS (Acute Respiratory Distress Syndrome).

Methods

Charts of all 20 patients with COVID-19 ARDS admitted to the ICU of a German University Hospital during the first wave of the pandemic between 22/03/2020 and 21/04/2020 were reviewed. Among screened 333 days, isoflurane was used in 97 days, while in 187 days, propofol was used for 12 h or more. The effect and dose of these two sedatives were compared. Mixed sedation days were excluded.

Results

Patients' age (median [interquartile range]) was 64 (60-68) years. They were invasively ventilated for 36 [21-50] days. End-tidal isoflurane concentrations were high (0.96 ± 0.41 Vol %); multiple linear regression yielded the ratio (isoflurane infusion rate)/(minute ventilation) as the single best predictor. Infusion rates were decreased under ECMO (3.5 ± 1.4 versus 7.1 ± 3.2 ml∙h-1; p < 0.001). In five patients, the maximum recommended dose of propofol of 4 mg∙hour-1∙kg-1ABW was exceeded on several days. On isoflurane compared to propofol days, neuro-muscular blocking agents (NMBAs) were used less frequently (11% versus 21%; p < 0.05), as were co-sedatives (7% versus 31%, p < 0.001); daily opioid doses were lower (720 [720-960] versus 1080 [720-1620] mg morphine equivalents, p < 0.001); and RASS scores indicated deeper levels of sedation (- 4.0 [- 4.0 to - 3.0] versus - 3.0 [- 3.6 to - 2.5]; p < 0.01).

Conclusion

Isoflurane provided sufficient sedation with less NMBAs, less polypharmacy and lower opioid doses compared to propofol. High doses of both drugs were needed in severely ill COVID-19 patients.

SUBMITTER: Kermad A 

PROVIDER: S-EPMC8225486 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

2022-02-28 | GSE197259 | GEO
| S-EPMC8441884 | biostudies-literature
2023-04-29 | GSE206264 | GEO
| S-EPMC8315516 | biostudies-literature
2022-02-28 | GSE197204 | GEO
2022-02-28 | GSE197258 | GEO
| S-EPMC7774924 | biostudies-literature
2024-10-22 | PXD057019 | Pride
2021-06-18 | GSE178404 | GEO
| S-EPMC7365850 | biostudies-literature